DE102004014783A1 - Gefriergetrocknete Formulierung von Antikörperkonjugaten - Google Patents

Gefriergetrocknete Formulierung von Antikörperkonjugaten Download PDF

Info

Publication number
DE102004014783A1
DE102004014783A1 DE102004014783A DE102004014783A DE102004014783A1 DE 102004014783 A1 DE102004014783 A1 DE 102004014783A1 DE 102004014783 A DE102004014783 A DE 102004014783A DE 102004014783 A DE102004014783 A DE 102004014783A DE 102004014783 A1 DE102004014783 A1 DE 102004014783A1
Authority
DE
Germany
Prior art keywords
conjugate
antibody
pharmaceutical composition
freeze
mytansinoid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
DE102004014783A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharma GmbH and Co KG
Original Assignee
Boehringer Ingelheim Pharma GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma GmbH and Co KG filed Critical Boehringer Ingelheim Pharma GmbH and Co KG
Priority to DE102004014783A priority Critical patent/DE102004014783A1/de
Priority to PCT/EP2004/014585 priority patent/WO2005065709A2/de
Priority to ARP040104838A priority patent/AR046774A1/es
Priority to TW093140566A priority patent/TW200533375A/zh
Publication of DE102004014783A1 publication Critical patent/DE102004014783A1/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/16—Cyclodextrin; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2884—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD44
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Die vorliegende Erfindung betrifft gefriergetrocknete (= lyophilisierte) pharmazeutische Zusammensetzungen von Antikörpern, bevorzugt von Antikörpern, die an ein Effektormolekül konjugiert sind. Insbesondere betrifft die vorliegende Erfindung stabile gefriergetrocknete Formulierungen von Antikörper-DM1-Komplexen. Des weiteren betrifft diese Erfindung Verfahren zur Lyophilisation von Antikörper-DM1-Komplexen.
DE102004014783A 2003-12-24 2004-03-24 Gefriergetrocknete Formulierung von Antikörperkonjugaten Withdrawn DE102004014783A1 (de)

Priority Applications (4)

Application Number Priority Date Filing Date Title
DE102004014783A DE102004014783A1 (de) 2004-03-24 2004-03-24 Gefriergetrocknete Formulierung von Antikörperkonjugaten
PCT/EP2004/014585 WO2005065709A2 (de) 2003-12-24 2004-12-22 Gefriergetrocknete formulierung von antikörperkonjugaten
ARP040104838A AR046774A1 (es) 2003-12-24 2004-12-22 Formulacion liofilizada de conjugados de anticuerpos
TW093140566A TW200533375A (en) 2003-12-24 2004-12-24 Freeze dried formulations of antibody conjugates

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102004014783A DE102004014783A1 (de) 2004-03-24 2004-03-24 Gefriergetrocknete Formulierung von Antikörperkonjugaten

Publications (1)

Publication Number Publication Date
DE102004014783A1 true DE102004014783A1 (de) 2005-10-20

Family

ID=35033900

Family Applications (1)

Application Number Title Priority Date Filing Date
DE102004014783A Withdrawn DE102004014783A1 (de) 2003-12-24 2004-03-24 Gefriergetrocknete Formulierung von Antikörperkonjugaten

Country Status (1)

Country Link
DE (1) DE102004014783A1 (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109641069A (zh) * 2016-08-19 2019-04-16 富士胶片富山化学株式会社 含有缓冲剂的组合物

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109641069A (zh) * 2016-08-19 2019-04-16 富士胶片富山化学株式会社 含有缓冲剂的组合物

Similar Documents

Publication Publication Date Title
WO2007147001A3 (en) Lyophilized formulations of anti-egfr antibodies
WO2007064968A3 (en) Stable pharmaceutical compositions of 5,10 methylenetetrahydrofolate
WO2004018000A3 (en) Compositions and methods for treating cancer using maytansinoid cd44 antibody immonoconjugates and chemotherapeutic agents
ATE267798T1 (de) Kombinierte wirkstoffe als methode zur gezielten wirkstoff-freisetzung
DK0938316T3 (da) Opioidantagonistholdig galenisk formulering
NZ602498A (en) Protein formulations and methods of making same
WO2000076551A3 (de) Verfahren zur herstellung einer injizierbaren arzneimittelzubereitung
UA85993C2 (ru) Конъюгат, который содержит бактериальный суперантиген и антительную составную, фармацевтическая композиция, которая его содержит, и способ лечения рака у млекопитающего
EP1445317A3 (de) Zusammensetzungen und Verfahren zur Diagnose und Behandlung von Krebs
TW200501941A (en) Heterobifunctional polymeric bioconjugates
WO2005099680A3 (en) Use of treprostinil to treat neuropathic diabetic foot ulcers
NZ599176A (en) Immunoconjugate formulations
WO2004050033A3 (en) Method of treating cancers
HRP20020787B1 (en) Method of treatment using ligand-immunogen conjugates
RS53548B1 (en) THERAPEUTIC FORMULATIONS OF KERATINocyte GROWTH FACTORS
WO2003075850A3 (en) Methods for alzheimer's disease treatment and cognitive enhancement
BR0109266A (pt) Composto, composição farmacêutica, método de tratamento de um mamìfero afetado com um câncer, método de liberação de um composto nas células de um mamìfero afetado com um câncer e uso do composto
WO2002083171A3 (en) Cancer treatment by using fap-alpha specific antibodies
WO2007062413A3 (en) Use of parp-1 inhibitors
WO2004112829A3 (en) Compositions and methods for the diagnosis and treatment of tumors of glial origin
WO2007056263A3 (en) Methods of treating cancer with high potency lipid-based platinum compound formulations administered intravenously
EA200201044A1 (ru) Фармацевтическая композиция с контролируемым высвобождением, содержащая мидодрин и/или десглимидодрин
WO2002041881A3 (de) Repinotan-kit
WO2002016602A3 (en) Compositions and methods for the diagnosis and treatment of tumor
DE102004014783A1 (de) Gefriergetrocknete Formulierung von Antikörperkonjugaten

Legal Events

Date Code Title Description
8139 Disposal/non-payment of the annual fee